RIPPLE-1: Evaluation of Safety and Efficacy of the IBE-814 Intravitreal Implant in Patients With Diabetic Macular Oedema and Macular Oedema Due to Retinal Vein Occlusion
Latest Information Update: 14 Jun 2024
At a glance
- Drugs Dexamethasone (Primary)
- Indications Branch retinal vein occlusion; Diabetic macular oedema; Retinal vein occlusion
- Focus Adverse reactions; Therapeutic Use
- Acronyms RIPPLE-1
- Sponsors Ripple Therapeutics
- 11 Jun 2024 Status changed from active, no longer recruiting to completed.
- 08 Mar 2023 Planned End Date changed from 30 Jun 2023 to 31 Aug 2024.
- 08 Mar 2023 Planned primary completion date changed from 30 Apr 2022 to 30 Apr 2024.